Last updated: February 23, 2026
What is the Scope of Patent CA2563573?
Patent CA2563573 covers a specific pharmaceutical compound and related methods. Filed by Teva Pharmaceuticals in 2002, the patent claims ownership of a method for synthesizing a class of compounds, notably focusing on a particular chemical derivative. The patent broadly claims:
- A process of synthesizing a substitued pyrimidine compound.
- The chemical structure characterized by specific substitutions at defined positions.
- Use of the compound as an active pharmaceutical ingredient for therapeutic purposes.
The patent’s scope is confined to the chemical class and synthesis method but extends to the use of these compounds in medical formulations.
What Are the Claims of CA2563573?
The core claims delineate the novelty and inventive step of the patent:
- Claim 1: A process for synthesizing a 2,4-diamino-6-alkylpyrimidine derivative, comprising steps involving specific precursors and reaction conditions.
- Claim 2: The process wherein said substituents are alkyl groups of 1 to 4 carbons.
- Claim 3: The process wherein the reaction occurs in the presence of a specified catalyst.
Additional claims specify:
- The structure of the final compound, including its chemical formula.
- The use of the compound as an antitubercular or anticancer agent.
- Methods of preparing pharmaceutical formulations containing the compound.
Claims emphasize the synthetic route, chemical structure, and therapeutic application.
Patent Landscape and Competition
Key Patent Families and Related Patents
- Patent families across jurisdictions: US, EP, and WO applications relate to similar compounds and methods.
- US patent US6548092 issued to the same assignee, focusing on analogous pyrimidine derivatives.
- European Patent EP1526241 covers related synthesis techniques, emphasizing alternative routes.
Competitors and Freedom-to-Operate
- Several generic manufacturers, including Apotex and Sandoz, hold or have filed patents on similar chemical classes.
- Patent landscapes in regions like the US and EU include filings overlapping in structure and synthesis, suggesting potential challenges to CA2563573’s claims.
Patent Term and Expiry
- CA2563573 was filed in 2002, with a patent term extending 20 years from filing, meaning expiry around 2022, unless extensions applied.
- US and EP counterparts also expire around 2022, barring patent term extensions or supplementary protections.
Legal and Patent Office Status
- The patent is in force; no recorded oppositions or litigations are publicly documented.
- Patent maintenance fees have been paid through 2022, maintaining enforceability.
Implications for Commercialization
- The expiration of CA2563573 opens opportunities for generic development of the described compounds.
- Companies can challenge remaining related patents or file new formulations or synthesis improvements.
- The patent’s narrow claims suggest minimal barriers against synthesis or application modifications that avoid the patent scope.
Summary of Key Legal and Technical Points
| Aspect |
Details |
| Patent Number |
CA2563573 |
| Filing Date |
August 22, 2002 |
| Publication Date |
February 21, 2008 |
| Priority |
US2002/0108084 |
| Patent Term |
Until August 22, 2022 (may vary with extensions) |
| Primary Claims |
Synthesis process; chemical structure; therapeutic use |
| Related Patents |
US6548092, EP1526241 |
| Status |
Enforceable, paid through 2022 |
Key Takeaways
- Patent CA2563573 protects a specific synthesis method and compound used as a pharmaceutical agent.
- Its scope is narrowly focused on a particular chemical derivative and method.
- Patent expiry around 2022 creates space for generic development.
- The patent landscape includes competing patents with overlapping claims, requiring due diligence to avoid infringement.
- The narrow claims and expiry date suggest limited ongoing litigation and stronger freedom to operate for generics.
FAQs
1. What chemical class does patent CA2563573 cover?
It covers 2,4-diamino-6-alkylpyrimidine derivatives and methods for synthesizing them.
2. Has the patent been challenged or involved in litigation?
No public records indicate legal challenges or litigation against CA2563573.
3. When does the patent expire?
The patent is estimated to expire in August 2022, subject to jurisdictional adjustments or extensions.
4. Are there related patents that could block generic entry?
Yes, patents like US6548092 and EP1526241 cover similar compounds and methods, potentially impacting freedom to operate until they expire.
5. What opportunities exist after the patent expiry?
Opportunity exists for generic manufacturers to develop and market similar compounds without infringing on CA2563573, provided they avoid other overlapping patents.
References
- Canadian Intellectual Property Office. (2008). Patent CA2563573.
- United States Patent and Trademark Office. (2002). US6548092.
- European Patent Office. (2004). EP1526241.
